Pharmaceutical major Zydus Cadila has informed that the company has received four product approvals from the United States Food and Drug Agency (USFDA).
The company has received approvals to market Pravastatin Sodium Tablets USP in 10, 20, 40 and 80 mg dosage and tentative approvals for Escitalopram Oxalate Tablets in 5, 10 and 20 mg, Losartan Potassium and Hydrochlorthiazide tablets 50mg/12.5 mg and 100mg/25mg and Anastrazole Tablets 1 mg.

Pravastatin Sodium, a lipid lowering agent falling in the cardiovascular segment while Escitalopram is used to treat depression. Further, Losartan Potassum and HCL used to treat hypertension while Anastrazole is a hormone therapy for breast cancer.

The US market for Pravastatin Sodium Tablets has been estimated at $1.9 billion in 2007, while the branded sales of Escitalopram Oxalate Tablets, were estimated at $3 billion.
While for the other two drugs sales were lower. US market Sales of Losartan Potassium and Hydrochlorthiazide Tablets, were estimated at $785 million, while Anastrazole Tablets, clocked revenue of $813 million.